Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma.
10.7534/j.issn.1009-2137.2013.06.021
- Author:
Shuang QU
1
;
Li-Sheng LIAO
2
;
Tian-Nan WEI
2
;
Yun LIN
2
;
Bin-Yu CHEN
2
;
Wei-Min CHEN
2
Author Information
1. Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China. E-mail:shuangerqu@163.com.
2. Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Boronic Acids;
administration & dosage;
therapeutic use;
Bortezomib;
Diphosphonates;
administration & dosage;
therapeutic use;
Drug Therapy, Combination;
Female;
Humans;
Intercellular Signaling Peptides and Proteins;
blood;
Male;
Middle Aged;
Multiple Myeloma;
blood;
drug therapy;
Pyrazines;
administration & dosage;
therapeutic use;
RANK Ligand;
blood
- From:
Journal of Experimental Hematology
2013;21(6):1482-1485
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the effect of bortezomib combined with bisphosphonates on serum levels of DKK-1 and RANKL in multiple myeloma patients, and to evaluate its role in the therapy of osteolytic lesion. Fourty-three patients with newly diagnosed and relapsed myeloma were divided into 2 groups. Twenty-three patients were treated with bortezomib combined with bisphosphonates (A group) and 20 patients were treated with bisphosphonates combined with traditional chemotherapy (B group). Serum levels of DKK-1 and RANKL were measured by ELISA before and after 4 cycles of chemotherapy. The results indicated that serum DKK-1 level significantly decreased in patients of A group (43.2 µg/L before vs 30.4 µg/L after 4 cycles of chemotherapy), and so did for serum RANKL level in A group (0.83 pmmol/L before vs 0.45 pmmol/L after 4 cycles of chemotherapy). While there was no significant differences in DKK-1 and RANKL serum level before therapy between A and B groups, but there was significant differences in DKK-1 and RANKL levels after 4 cycles of chemotherapy (P < 0.05). It is concluded that bortezomib combined with bisphosphonates obviously reduce the serum levels of DKK-1 and RANKL, thus has beneficial effect on osteolytic lesion.
